Study search
Go straight to the source
Search PubMed, Europe PMC and ClinicalTrials.gov from one box. Results come from the indexes themselves, newest first, each linked to its original record.
Amiravo's reviewed summary: Mazdutide research reference →
55 records · showing 25 · open this search in PubMed
- PubMedReviewThe pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.Journal of diabetes and metabolic disorders · 2026 Dec
- PubMedRandomized Controlled TrialMulticenter StudyClinical Trial, Phase IIEfficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2026 Nov
- PubMedThe GLP-1R/GCGR Dual Agonist Mazdutide Attenuates Liver Steatosis and Decreases Circulating Cholesterol Levels in Mice With Metabolic Dysfunction-Associated Steatotic Liver Disease.Diabetes, obesity & metabolism · 2026 Oct 14
- PubMedReviewThe Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026 Oct 11
- PubMedDevelopment and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.Journal of chromatography. A · 2026 Oct 11
- PubMedSystematic ReviewMeta-AnalysisEfficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.Diabetes, obesity & metabolism · 2026 Oct
- PubMedEfficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.Diabetes, obesity & metabolism · 2026 Sep 29
- PubMedAssessing the quality and reliability of health information on GLP-1 receptor agonists on TikTok and Bilibili: a cross-sectional analysis of the public health infodemic.Therapeutic advances in endocrinology and metabolism · 2026
- PubMedComparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.BMJ medicine · 2026
- PubMedRenoprotective effects of tubular glucagon receptor activation mediated by V-ATPase.Science advances · 2026 Aug 7
- PubMedReviewResearch Support, Non-U.S. Gov'tCardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus.Journal of the American Heart Association · 2026 Aug 4
- PubMedCommentMazdutide and Orforglipron-New Evidence in Obesity and Diabetes.JAMA · 2026 Aug 4
- PubMedTreatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.JAMA · 2026 Aug 4
- PubMedRandomized Controlled TrialMulticenter StudyClinical Trial, Phase IIITreatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.JAMA · 2026 Aug 4
- PubMedReviewBeyond weight loss: multisystem benefits of obesity medications.The lancet. Diabetes & endocrinology · 2026 Aug
- PubMedEfficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2026 Jul 24
- PubMedSystematic ReviewNetwork Meta-AnalysisComparative StudyComparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2026 Jul 8
- PubMedReviewObesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.Metabolism open · 2026 Jun
- PubMedMeta-AnalysisReviewEfficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.Diabetes, obesity & metabolism · 2026 Jun
- PubMedRandomized Controlled TrialClinical Trial, Phase IIMazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized controlled trial.Med (New York, N.Y.) · 2026 May 8
- PubMedReviewPatent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.Expert opinion on therapeutic patents · 2026 May
- PubMedRandomized Controlled TrialClinical Trial, Phase IIIComparative StudyMazdutide versus dulaglutide in Chinese adults with type 2 diabetes.Nature · 2026 Apr
- PubMedRandomized Controlled TrialClinical Trial, Phase IIIResearch Support, Non-U.S. Gov'tMazdutide versus placebo in Chinese adults with type 2 diabetes.Nature · 2026 Apr
- PubMedReviewNovel GLP-1-based Medications for Type 2 Diabetes and Obesity.Endocrine reviews · 2026 Mar 11
- PubMedNetwork Meta-AnalysisComparative StudyReviewComparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.Endocrinology, diabetes & metabolism · 2026 Mar
Queries go directly from your browser to NCBI, EMBL-EBI and ClinicalTrials.gov; Amiravo does not store them. Study-type labels come from the indexes and can be wrong. A record's presence says nothing about whether a compound works or is safe. PubMed data via NCBI E-utilities; see NCBI policies.